Assessment of treatment with orotate magnesium in early postoperative period of patients with cardiac insufficiency and coronary artery by-pass grafts (ATOMIC)
Branea, I.; Gaiţă, D.; Drăgulescu, I.; Socoteanu, I.; Luca, C.; Mancaş, S.; Drăgan, S.; Iurciuc, M.; Velimirovici, D.; Gaşpar, M.; Fluture, A.; Ionac, A.; Deutsch, P.; Pescariu, S.; Petrescu, L.; Branea, H.; Mut, B.; Dină, C.; Crâsnic, M.; Sarău, C.A.
Romanian Journal of Internal Medicine 37(3): 287-296
1999
ISSN/ISBN: 1220-4749 PMID: 15532307 Document Number: 8325
The benefit of the treatment with magnesium orotate (magnerot) was assessed in a randomised, single blind and placebo controlled study. Respecting the inclusion criteria were selected 32 patients with ischemia chronic failure in early postoperative period after CABG. The main improvements induced by magnesium orotate are the increase in exercise capacity (distance ambulated during 6 minutes walk test and ergospirometric parameters) and the reduction of ventricular premature beats. The treatment was well tolerated and the adverse reactions were not significant. The study strongly suggests the benefit of magnesium orotate added to classical antiischemic therapy in the complex management of coronary patients after CABG.
Document emailed within 1 workday
